Zobrazeno 1 - 10
of 68
pro vyhledávání: '"Hervé, Broly"'
Publikováno v:
mAbs, Vol 15, Iss 1 (2023)
ABSTRACTThe COVID-19 pandemic highlighted the urgent need for life-saving treatments, including vaccines, drugs, and therapeutic antibodies, delivered at unprecedented speed. During this period, recombinant antibody research and development cycle tim
Externí odkaz:
https://doaj.org/article/54b1178b4aac4290baf8422450257b3c
Autor:
Kevin Botelho Ferreira, Asma Benlegrimet, Gabriel Diane, Victor Pasquier, Raphael Guillot, Marc De Poli, Loïc Chappuis, Nandita Vishwanathan, Jonathan Souquet, Hervé Broly, Jean‐Marc Bielser
Publikováno v:
Biotechnology progressREFERENCES. 38(4)
Implementation of continuous in lieu of batch upstream processing (USP) and downstream process (DSP) for the production of recombinant therapeutic protein is a significant paradigm change. The present report describes how the first kilograms of monoc
Autor:
null Kevin Botelho Ferreira, null Asma Benlegrimet, null Gabriel Diane, null Victor Pasquier, null Raphael Guillot, null Marc De Poli, null Loïc Chappuis, null Nandita Vishwanathan, null Jonathan Souquet, null Hervé Broly, null Jean‐Marc Bielser
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::daa0c07a3f13087f41a6378c290c01d1
https://doi.org/10.1002/btpr.3259/v2/response1
https://doi.org/10.1002/btpr.3259/v2/response1
Publikováno v:
Trends in Biotechnology. 38:1154-1168
The clinical efficacy and safety of therapeutic monoclonal antibodies (mAbs) are significantly affected by their Fc-glycosylation profile. High mannose-type N-glycans (HM) affect efficacy (in terms of antibody-dependent cell cytotoxicity), pharmacoki
Autor:
Caterina Ruggeri, Hervé Broly, Moritz Wolf, Fabian Feidl, Massimo Morbidelli, Sebastian Vogg, Matevz Podobnik, Alessandro Butté, Nicole Ulmer, Ruben Wälchli, Jonathan Souquet
Publikováno v:
Biotechnology and Bioengineering. 117:1367-1380
Integrated continuous manufacturing is entering the biopharmaceutical industry. The main drivers range from improved economics, manufacturing flexibility, and more consistent product quality. However, studies on fully integrated production platforms
Autor:
James Angelo, Ruben Wälchli, Sebastian Vogg, Fabian Feidl, Zheng Jian Li, Jonathan Souquet, Sanchayita Ghose, Xavier Le Saoût, Hervé Broly, Mariana Ressurreição, Massimo Morbidelli, Xuankuo Xu
Publikováno v:
Biotechnology and Bioengineering, 117 (3)
Monoclonal antibodies (mAbs) and related recombinant proteins continue to gain importance in the treatment of a great variety of diseases. Despite significant advances, their manufacturing can still present challenges owing to their molecular complex
Autor:
Michele Vigolo, Christine Kowalczyk-Quintas, Özkan Yalkinoglu, Daniela Willen, Mahya Eslami, Benjamin Peter, Eileen Samy, Michaela Golob, Pascal Schneider, Hervé Broly, Laure Willen, Sonia Schuepbach-Mallepell
Publikováno v:
British journal of pharmacology, vol. 176, no. 20, pp. 4019-4033
British Journal of Pharmacology
British Journal of Pharmacology
Background and Purpose The TNF family ligands, B cell activating factor of the TNF family (BAFF, also known as B lymphocyte stimulator, BLyS) and a proliferation‐inducing ligand (APRIL), share the transmembrane activator and calcium‐modulator and
Autor:
Antu K. Dey, Angela Lim, Jessica P. Dawson, Adin Ross-Gillespie, Mara Rossi, Mirva Hejjaoui Simoneau, Cyril Boucher, Wolf Palinsky, Mark B. Feinberg, Joseph G. Jardine, Bernhard Valldorf, Hervé Broly, Dennis R. Burton, Thomas Hassell, Philippe Dupraz, Rita Agostinetto, Devin Sok
Publikováno v:
Biotechnology and Bioengineering
Therapeutic proteins, including monoclonal antibodies, are typically manufactured using clonally‐derived, stable host cell lines, since consistent and predictable cell culture performance is highly desirable. However, selecting and preparing banks
Autor:
Rita Agostinetto, Jessica Dawson, Angela Lim, Mirva Hejjaoui-simoneau, Cyril Boucher, Bernhard Valldorf, Adin Ross-gillespie, Joseph Jardine, Devin Sok, Dennis Burton, Thomas Hassell, Hervé Broly, Wolf Palinsky, Philippe Dupraz, Mark Feinberg, Antu Dey
Therapeutic proteins, including monoclonal antibodies, are typically manufactured using clonally-derived, stable host cell lines, since consistent and predictable cell culture performance is highly desirable. However, selecting and preparing banks of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::66208bd81826345146315939eff017c4
https://doi.org/10.22541/au.163251349.96835693/v1
https://doi.org/10.22541/au.163251349.96835693/v1
Publikováno v:
Trends in pharmacological sciences. 42(11)
The incorporation of the non-human N-glycolylneuraminic acid (Neu5Gc) in therapeutic recombinant proteins raises clinical concerns due to its immunogenic potential and the high prevalence of pre-existing anti-Neu5Gc antibodies in humans. The scientif